Literature DB >> 9170991

Quality of life in women with ovarian cancer.

M Ersek1, B R Ferrell, K H Dow, C H Melancon.   

Abstract

Despite growing interest in quality of life (QOL) as an important variable in nursing and health care, little research focuses on QOL in women with ovarian cancer (OVCA). The purpose of this study was to examine QOL in OVCA survivors. The convenience sample consisted of 152 women in all disease stages. Quantitative data were collected using the QOL-Cancer Survivors tool and a demographic sheet. Qualitative data were collected by asking participants to write their definitions and experiences of QOL since their diagnosis. Reliability and validity of all data and findings were established. Findings reveal that QOL is moderately high for this group of cancer survivors, despite some specific negative facets of the illness and treatment experience. Qualitative analysis elaborates the four domains of Ferrell's QOL model: physical, psychological, social, and spiritual well-being. Qualitative data also reflect the complexity of the cancer experience.

Entities:  

Mesh:

Year:  1997        PMID: 9170991     DOI: 10.1177/019394599701900305

Source DB:  PubMed          Journal:  West J Nurs Res        ISSN: 0193-9459            Impact factor:   1.967


  13 in total

1.  Problems Experienced by Ovarian Cancer Survivors During Treatment.

Authors:  Jessica Keim-Malpass; Shannon L Mihalko; Greg Russell; Doug Case; Brigitte Miller; Nancy E Avis
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2017-06-03

2.  Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.

Authors:  Electra Paskett; James Herndon; Kathleen Donohue; Michelle Naughton; Stephen Grubbs; Michael Pavy; Martee Hensley; Nancy Stark; Alice Kornblith; Marisa Bittoni
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

3.  Quality of life among women after surgery for ovarian cancer.

Authors:  Dena Schulman-Green; Elizabeth Ercolano; Michael Dowd; Peter Schwartz; Ruth McCorkle
Journal:  Palliat Support Care       Date:  2008-09

Review 4.  Cancer-related fatigue: the approach and treatment.

Authors:  Carmen P Escalante; Ellen F Manzullo
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

5.  Feasibility of an ovarian cancer quality-of-life psychoeducational intervention.

Authors:  Shirley Otis-Green; Betty Ferrell; Virginia Sun; Maren Spolum; Robert Morgan; Deborah Macdonald
Journal:  J Cancer Educ       Date:  2008       Impact factor: 2.037

Review 6.  The taxanes: toxicity and quality of life considerations in advanced ovarian cancer.

Authors:  J P Guastalla; V Diéras
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

7.  Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study.

Authors:  Dominique Koensgen; Guelten Oskay-Oezcelik; Ioanna Katsares; Ulla Walle; Christine Klapp; Alexander Mustea; Dirk Stengel; Franz Porzsolt; Werner Lichtenegger; Jalid Sehouli
Journal:  Support Care Cancer       Date:  2009-09-17       Impact factor: 3.603

Review 8.  Ovarian cancer survivors' quality of life: a systematic review.

Authors:  D Ahmed-Lecheheb; F Joly
Journal:  J Cancer Surviv       Date:  2016-02-17       Impact factor: 4.442

9.  Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.

Authors:  Electra D Paskett; James E Herndon; Jeannette M Day; Nancy N Stark; Eric P Winer; Stephen S Grubbs; Michael D Pavy; Charles L Shapiro; Marcy A List; Martee L Hensley; Michelle A Naughton; Alice B Kornblith; Karleen R Habin; Gini F Fleming; Marisa A Bittoni
Journal:  Psychooncology       Date:  2008-11       Impact factor: 3.894

10.  Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer.

Authors:  Digant Gupta; Donald P Braun; Edgar D Staren; Maurie Markman
Journal:  J Ovarian Res       Date:  2013-03-08       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.